EB1006

EB1006 is a biosimilar monoclonal antibody candidate currently in preclinical development by Eden Biologics (formerly JHL Biotech). It is being developed for the treatment of various oncology indications. As a biosimilar, it is designed to be highly similar to an already approved reference biologic drug, although the specific reference product for EB1006 has not been publicly disclosed by the developer. The drug is part of Eden Biologics' pipeline of biosimilar candidates aimed at increasing access to high-value biologic therapies in the field of oncology. Given its classification in the oncology pipeline alongside other monoclonal antibody biosimilars, it is intended to replicate the safety and efficacy profile of a blockbuster oncology biologic.